AU2002227498A1 - Tumor antigen - Google Patents

Tumor antigen

Info

Publication number
AU2002227498A1
AU2002227498A1 AU2002227498A AU2749802A AU2002227498A1 AU 2002227498 A1 AU2002227498 A1 AU 2002227498A1 AU 2002227498 A AU2002227498 A AU 2002227498A AU 2749802 A AU2749802 A AU 2749802A AU 2002227498 A1 AU2002227498 A1 AU 2002227498A1
Authority
AU
Australia
Prior art keywords
tumor antigen
peptide
polynucleotide
tumor
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002227498A
Other languages
English (en)
Inventor
Kyogo Itoh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2002227498A1 publication Critical patent/AU2002227498A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002227498A 2000-07-31 2001-07-30 Tumor antigen Abandoned AU2002227498A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-231814 2000-07-31
JP2000231814 2000-07-31
PCT/JP2001/006526 WO2002010369A1 (fr) 2000-07-31 2001-07-30 Antigene associe aux tumeurs

Publications (1)

Publication Number Publication Date
AU2002227498A1 true AU2002227498A1 (en) 2002-02-13

Family

ID=18724591

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002227498A Abandoned AU2002227498A1 (en) 2000-07-31 2001-07-30 Tumor antigen

Country Status (9)

Country Link
US (6) US7148326B2 (fr)
EP (1) EP1306431B1 (fr)
JP (1) JP4900884B2 (fr)
AT (1) ATE389668T1 (fr)
AU (1) AU2002227498A1 (fr)
CA (1) CA2417570C (fr)
DE (1) DE60133287T2 (fr)
ES (1) ES2304398T3 (fr)
WO (1) WO2002010369A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1473564A4 (fr) * 2001-09-18 2008-12-10 Greenpeptide Co Ltd Procede de detection de l'immunite cellulaire et son application sur des medicaments
JP4721903B2 (ja) * 2004-01-29 2011-07-13 大日本住友製薬株式会社 新規腫瘍抗原蛋白質及びその利用
US20080200088A1 (en) * 2007-02-21 2008-08-21 Chong Pyung An Method for reducing interference fringes in a display device
CN104922650B (zh) * 2007-09-18 2018-04-24 亮径生物疗法有限公司 Ctl诱导剂组合物
EP2123748A1 (fr) * 2008-05-20 2009-11-25 Institut Pasteur 2'-5'-oligoadénylate synthétase 3 pour prévenir et traiter une infection par virus à ARN à brin unique de sens positif
CA2759333A1 (fr) 2009-04-22 2010-10-28 Merck Patent Gmbh Proteines de fusion a des anticorps avec des sites de liaison a fcrn modifies
MX2011013452A (es) 2009-07-02 2012-04-30 Ith Immune Therapy Holdings Ab Tratamiento de cancer basado en exosomas.
CN102782500B (zh) * 2010-03-03 2015-03-18 东丽株式会社 胃癌检测用的标志物和胃癌检测方法
WO2012082841A2 (fr) * 2010-12-14 2012-06-21 University Of Maryland, Baltimore Lymphocytes t exprimant un récepteur d'antigène chimérique anti-étiquette universel et méthodes de traitement du cancer
JPWO2013031756A1 (ja) * 2011-08-29 2015-03-23 東レ株式会社 大腸癌または食道癌の検出用マーカー及び検査方法
CN107881158B (zh) 2012-09-11 2021-11-16 肿瘤疗法科学股份有限公司 Ube2t肽及包含它们的疫苗
WO2014136814A1 (fr) 2013-03-08 2014-09-12 大鵬薬品工業株式会社 Nouveau peptide portant 5 épitopes de ctl liés
WO2015060235A1 (fr) * 2013-10-21 2015-04-30 大鵬薬品工業株式会社 Nouveau peptide à quatre épitopes ctl
SG10202111399YA (en) 2015-12-22 2021-11-29 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201604458D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
WO2018160622A1 (fr) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions et méthodes de thérapie par lymphocytes t car
WO2019004415A1 (fr) * 2017-06-30 2019-01-03 国立大学法人大阪大学 Procédé pour prédire l'effet d'une immunothérapie antitumorale à l'aide d'une activité cytotoxique tumorale de lymphocytes t du sang périphérique comme indice
CN111246852A (zh) 2017-10-26 2020-06-05 大塚制药株式会社 含有磷酸肌醇的组合物
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
EP3815711A4 (fr) 2018-06-29 2022-08-10 Taiho Pharmaceutical Co., Ltd. Agent antitumoral et sa méthode d'évaluation
AU2020411439A1 (en) 2019-12-26 2022-08-04 Taiho Pharmaceutical Co., Ltd. Agent for adjuvant therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874231A (en) * 1994-08-22 1999-02-23 Mcgill University Methods of screening for non-hormone compounds which effect modulation of polypeptide translation
US5936078A (en) 1995-12-12 1999-08-10 Kyowa Hakko Kogyo Co., Ltd. DNA and protein for the diagnosis and treatment of Alzheimer's disease
CN1173896A (zh) * 1995-12-12 1998-02-18 协和发酵工业株式会社 新的dna、新的多肽和新的抗体
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
JP2000189168A (ja) * 1998-12-28 2000-07-11 Hiroshi Handa 新規転写伸長抑制因子
AU6321400A (en) * 1999-08-17 2001-03-13 Protegene Inc. Human proteins having hydrophobic domains and dnas encoding these proteins

Also Published As

Publication number Publication date
ES2304398T3 (es) 2008-10-16
DE60133287D1 (de) 2008-04-30
US7524930B2 (en) 2009-04-28
EP1306431B1 (fr) 2008-03-19
US20070031433A1 (en) 2007-02-08
US20030175288A1 (en) 2003-09-18
CA2417570C (fr) 2010-12-07
ATE389668T1 (de) 2008-04-15
EP1306431A1 (fr) 2003-05-02
US7148326B2 (en) 2006-12-12
US20070071767A1 (en) 2007-03-29
US7427660B2 (en) 2008-09-23
JP4900884B2 (ja) 2012-03-21
US7404270B2 (en) 2008-07-29
WO2002010369A1 (fr) 2002-02-07
US7408037B2 (en) 2008-08-05
EP1306431A4 (fr) 2004-08-18
CA2417570A1 (fr) 2003-01-31
US20070066804A1 (en) 2007-03-22
US7432354B2 (en) 2008-10-07
US20070031432A1 (en) 2007-02-08
DE60133287T2 (de) 2009-03-26
US20070031431A1 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
AU2002227498A1 (en) Tumor antigen
WO2001075067A8 (fr) Nouveaux acides nucleiques et polypeptides
WO2001057188A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001057190A3 (fr) Acides nucleiques et polypeptides
WO2002022660A3 (fr) Noveaux acides nucleiques et polypeptides
WO2001066689A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001053312A8 (fr) Nouveaux acides nucleiques et polypeptides
WO2001053455A3 (fr) Nouveaux acides nucleiques et polypeptides associes
WO2002031111A3 (fr) Acides nucleiques et polypeptides
WO2001088088A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002059260A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2003054152A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2003025148A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002070539A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2003023013A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002081731A3 (fr) Nouveaux acides nucleiques et polypeptides
GB9823897D0 (en) Immunotherapeutic methods and molecules
WO2003029271A3 (fr) Nouveaux acides nucleiques et polypeptides
NZ511991A (en) Interleukin-17 related mammalian cytokines. Polynucleotides encoding them. uses
WO2002018424A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001079449A3 (fr) Acides nucleiques et polypeptides nouveaux
DE60044193D1 (en) Tumor antigen
WO2002044340A3 (fr) Nouveaux acides nucleiques et polypeptides
WO1999057277A3 (fr) Proteines basb019 et genes issus de moxarella catarrhalis, antigenes, anticorps et utilisation de ces derniers
WO2003008450A1 (fr) Antigenes tumoraux